Boston Scientific Corp (XTER:BSX)
€ 86.5 -0.5 (-0.57%) Market Cap: 126.52 Bil Enterprise Value: 134.81 Bil PE Ratio: 74.93 PB Ratio: 6.45 GF Score: 79/100

Boston Scientific Corp Investor Update at NANS 2020 Transcript

Jan 24, 2020 / 03:00PM GMT
Susan Vissers Lisa
Boston Scientific Corporation - VP of IR

All right. Good morning, everyone. Thank you very, very much for joining Boston Scientific here at the North American Neuromodulation Society Investor Update. And for those of you on the webcast, I can attest, I'm grateful or relieved, I guess, there is a full room here in Las Vegas at 7:00 a.m., which is impressive, I think.

So very excited to give you a deep dive on our Neuromodulation business, one of our most exciting businesses. And we have 3 representatives here. Maulik Nanavaty, I think you all know him. He leads the neuromodulation team, Senior Vice President and President of Neuromod. And then familiar faces as well, Jesse Feinkind is the Vice President for our Global Pain franchise. And then he'll be followed by comments -- by Milad Girgis, who is the Vice President for our Global Brain Modulation franchise. There's also several members of the neuromodulation team here in the room. And so after our prepared comments, we look forward to your questions, and we'll wrap up promptly at 8 Vegas time.

So without further ado

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot